Biohaven’s taldefgrobep alfa may have missed the mark for spinal muscular atrophy, failing a Phase 3 trial in November 2024, but the biologic did help patients lose weight while preserving lean muscle and bone density—a holy grail of obesity treatments. Now the company is hoping the drug will help pivot its pipeline toward the lucrative weight loss market.
“We’re a small biopharma company, and when we have good assets, we do a full…
more
Source www.biospace.com
FTC: We use income earning affiliate links. More on Sposored links.
Terms of use and third-party services. More here.
Terms of use and third-party services. More here.